Reaserch Advances in the Treatment of Primary Immune Thrombocytopenia--Review.
10.19746/j.cnki.issn.1009-2137.2021.03.052
- Author:
Xin-Yu LI
1
;
Yang HE
2
;
Chang-Geng RUAN
1
Author Information
1. Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China.
2. Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China,E-mail: heyang1963@163.com.
- Publication Type:Review
- MeSH:
Adult;
Hemorrhage;
Humans;
Platelet Count;
Purpura, Thrombocytopenic, Idiopathic/drug therapy*;
Splenectomy
- From:
Journal of Experimental Hematology
2021;29(3):983-987
- CountryChina
- Language:Chinese
-
Abstract:
Primary immune thrombocytopenia (ITP) is a blood system disease mediated by autoimmune mechanism. Currently, the goal of treatment for primary ITP is to keep patients' peripheral platelet count at a safe level to prevent severe bleeding. Recently, avatrombopag and fostamatinib have been approved by the FDA for the treatment of primary ITP in adults, while new drugs such as rozanolixizumab, efgartigimod, PRTX-100, decitabine and atorvastatin have shown efficacy in early clinical trials. This review summarizes the current accepted therapies for the clinical treatment of primary ITP in adults, and briefly discuss the progress of new therapies.
